FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176500350> ?p ?o ?g. }

• W2176500350 endingPage "887" @default.
• W2176500350 startingPage "S" @default.
• W2176500350 abstract "Aim: Adalimumab (ADA) has been shown to be an effective treatment for inducing and maintaining clinical remission and/or response in children with moderate to severe Crohn's disease (CD)1. Although the standard adult dose (SD) ADA maintenance therapy exhibited generally greater efficacy than low dose (LD)1, the influence of baseline (BL) disease severity on outcomes has not been determined. Methods: In IMAgINE11, patients (pts) aged 6-17 years that had a PCDAI score .30 at BL, with CD resistant or intolerant to conventional therapy, including prior infliximab (IFX), received open-label induction ADA at weeks (wks) 0/2 according to bodyweight (≥40kg, 160/80mg;,40kg, 80/40mg). At wk4, 188 randomized pts (ITT population) received either double-blind SD ( ≥40kg, 40mg every other wk (eow); ,40kg, 20mg eow) or LD (≥40kg, 20mg eow; ,40kg, 10mg eow) maintenance therapy. After wk12, pts could move to blinded weekly (ew) dosing for disease flare or non-response. Clinical remission (PCDAI≤10) and response (PCDAI decrease ≥15 points from BL) were measured at wk52. Subgroup analyses by disease severity, based on the median BL PCDAI observed for the study population (less severe CD, PCDAI,40; more severe CD, PCDAI≥40), and also by prior IFX use were performed. Non-responder imputation was used for missing data or after switch to ew therapy. Treatment-emergent adverse events (AE) were reported as events/100pt-years (E/100PY) for any pt receiving at least one dose of ADA. Results: Greater clinical remission and response was achieved with SD ADA therapy compared to LD at wk52 in pts with more severe disease, with the greatest difference between doses occurring in IFX Naive pts. For pts with less severe CD, similar rates of remission and response were observed between SD and LD ADA (Table). Switch to ew dosing occurred most frequently in pts with more severe CD receiving LD ADA (55.6%) than in pts with less severe CD receiving the same dose (43.9%). For pts receiving SD ADA, escalation to ew dosing occurred in a similar percentage of pts, regardless of BL disease severity (35.9%, less severe; 38.9%, more severe). The overall rate of AEs was similar between dosing groups for either pt population. For pts with less severe CD, serious AEs (SAEs) were higher with SD (32.0 E/100PY) than LD ADA (17.6 E/100PY), whereas a similar rate of SAEs was observed between SD and LD ADA in pts with more severe disease (54.8 vs 64.5 E/ 100PY, respectively). No malignancies, TB, congestive heart failure or deaths were reported. Conclusion: At wk52, SD maintenance ADA was a more effective therapy than LD for children with more severe CD, whereas pts with less severe disease benefitted equally from both doses. The greatest remission and response rates were observed for IFX-Naive pts. The overall safety profile was similar for SD and LD ADA treatment. 1.Hyams 2012 Gastroenterology;143:365 Clinical outcomes in pediatric CD pts with eow SD vs eow LD ADA (ITT population)" @default.
• W2176500350 created "2016-06-24" @default.
• W2176500350 creator A5006726610 @default.
• W2176500350 creator A5018825142 @default.
• W2176500350 creator A5023009175 @default.
• W2176500350 creator A5029299515 @default.
• W2176500350 creator A5044105377 @default.
• W2176500350 creator A5054537181 @default.
• W2176500350 creator A5056966450 @default.
• W2176500350 creator A5064024135 @default.
• W2176500350 date "2013-05-01" @default.
• W2176500350 modified "2023-10-18" @default.
• W2176500350 title "Tu1944 Efficacy and Safety of Standard vs Low Dose Adalimumab Maintenance Therapy As a Function of Disease Severity in Pediatric Patients With Crohn's Disease: Subanalysis of Imagine 1" @default.
• W2176500350 doi "https://doi.org/10.1016/s0016-5085(13)63300-4" @default.
• W2176500350 hasPublicationYear "2013" @default.
• W2176500350 type Work @default.
• W2176500350 sameAs 2176500350 @default.
• W2176500350 citedByCount "1" @default.
• W2176500350 countsByYear W21765003502019 @default.
• W2176500350 crossrefType "journal-article" @default.
• W2176500350 hasAuthorship W2176500350A5006726610 @default.
• W2176500350 hasAuthorship W2176500350A5018825142 @default.
• W2176500350 hasAuthorship W2176500350A5023009175 @default.
• W2176500350 hasAuthorship W2176500350A5029299515 @default.
• W2176500350 hasAuthorship W2176500350A5044105377 @default.
• W2176500350 hasAuthorship W2176500350A5054537181 @default.
• W2176500350 hasAuthorship W2176500350A5056966450 @default.
• W2176500350 hasAuthorship W2176500350A5064024135 @default.
• W2176500350 hasBestOaLocation W21765003501 @default.
• W2176500350 hasConcept C126322002 @default.
• W2176500350 hasConcept C177713679 @default.
• W2176500350 hasConcept C2776485726 @default.
• W2176500350 hasConcept C2776694085 @default.
• W2176500350 hasConcept C2778283404 @default.
• W2176500350 hasConcept C2779134260 @default.
• W2176500350 hasConcept C2779280984 @default.
• W2176500350 hasConcept C2780132546 @default.
• W2176500350 hasConcept C71924100 @default.
• W2176500350 hasConceptScore W2176500350C126322002 @default.
• W2176500350 hasConceptScore W2176500350C177713679 @default.
• W2176500350 hasConceptScore W2176500350C2776485726 @default.
• W2176500350 hasConceptScore W2176500350C2776694085 @default.
• W2176500350 hasConceptScore W2176500350C2778283404 @default.
• W2176500350 hasConceptScore W2176500350C2779134260 @default.
• W2176500350 hasConceptScore W2176500350C2779280984 @default.
• W2176500350 hasConceptScore W2176500350C2780132546 @default.
• W2176500350 hasConceptScore W2176500350C71924100 @default.
• W2176500350 hasIssue "5" @default.
• W2176500350 hasLocation W21765003501 @default.
• W2176500350 hasOpenAccess W2176500350 @default.
• W2176500350 hasPrimaryLocation W21765003501 @default.
• W2176500350 hasRelatedWork W2086458027 @default.
• W2176500350 hasRelatedWork W2325222222 @default.
• W2176500350 hasRelatedWork W2411629461 @default.
• W2176500350 hasRelatedWork W2606045646 @default.
• W2176500350 hasRelatedWork W2619350174 @default.
• W2176500350 hasRelatedWork W2790226571 @default.
• W2176500350 hasRelatedWork W2794241916 @default.
• W2176500350 hasRelatedWork W3191351618 @default.
• W2176500350 hasRelatedWork W4250688114 @default.
• W2176500350 hasRelatedWork W2189383814 @default.
• W2176500350 hasVolume "144" @default.
• W2176500350 isParatext "false" @default.
• W2176500350 isRetracted "false" @default.
• W2176500350 magId "2176500350" @default.
• W2176500350 workType "article" @default.